BMS flips negative NICE ruling on Opdivo, winning thumbs-up for preventing melanoma relapse

30th November 2018 Uncategorised 0

In September, Britain’s drug-cost watchdog National Institute for Health and Care Excellence (NICE) said Bristol-Myers Squibb’s PD-1 blocker Opdivo should not be covered for preventing relapses in melanoma patients after surgery. The company successfully appealed the decision—scoring an important win for a drug that’s seen its share of disappointments.

More: BMS flips negative NICE ruling on Opdivo, winning thumbs-up for preventing melanoma relapse
Source: fierce